638 related articles for article (PubMed ID: 28083784)
1. Understanding Parkinson's Disease through the Use of Cell Reprogramming.
Playne R; Connor B
Stem Cell Rev Rep; 2017 Apr; 13(2):151-169. PubMed ID: 28083784
[TBL] [Abstract][Full Text] [Related]
2. Potential application of induced pluripotent stem cells in cell replacement therapy for Parkinson's disease.
Chen LW; Kuang F; Wei LC; Ding YX; Yung KK; Chan YS
CNS Neurol Disord Drug Targets; 2011 Jun; 10(4):449-58. PubMed ID: 21495962
[TBL] [Abstract][Full Text] [Related]
3. Pluripotent stem cell derived dopaminergic subpopulations model the selective neuron degeneration in Parkinson's disease.
Oosterveen T; Garção P; Moles-Garcia E; Soleilhavoup C; Travaglio M; Sheraz S; Peltrini R; Patrick K; Labas V; Combes-Soia L; Marklund U; Hohenstein P; Panman L
Stem Cell Reports; 2021 Nov; 16(11):2718-2735. PubMed ID: 34678205
[TBL] [Abstract][Full Text] [Related]
4. Human induced pluripotent stem cell-derived neurons improve motor asymmetry in a 6-hydroxydopamine-induced rat model of Parkinson's disease.
Han F; Wang W; Chen B; Chen C; Li S; Lu X; Duan J; Zhang Y; Zhang YA; Guo W; Li G
Cytotherapy; 2015 May; 17(5):665-79. PubMed ID: 25747741
[TBL] [Abstract][Full Text] [Related]
5. Progress in Dopaminergic Cell Replacement and Regenerative Strategies for Parkinson's Disease.
Chen W; Huang Q; Ma S; Li M
ACS Chem Neurosci; 2019 Feb; 10(2):839-851. PubMed ID: 30346716
[TBL] [Abstract][Full Text] [Related]
6. Implications of Parkinson's disease pathophysiology for the development of cell replacement strategies and drug discovery in neurodegenerative diseases.
Pan-Montojo F; Funk RH
CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):907-20. PubMed ID: 23131153
[TBL] [Abstract][Full Text] [Related]
7. Generation of dopamine neuronal-like cells from induced neural precursors derived from adult human cells by non-viral expression of lineage factors.
Playne R; Jones K; Connor B
J Stem Cells Regen Med; 2018; 14(1):34-44. PubMed ID: 30018471
[TBL] [Abstract][Full Text] [Related]
8. Treatment of Parkinson's Disease through Personalized Medicine and Induced Pluripotent Stem Cells.
Stoddard-Bennett T; Reijo Pera R
Cells; 2019 Jan; 8(1):. PubMed ID: 30621042
[TBL] [Abstract][Full Text] [Related]
9. Engraftable Induced Pluripotent Stem Cell-Derived Neural Precursors for Brain Repair.
Zygogianni O; Kouroupi G; Taoufik E; Matsas R
Methods Mol Biol; 2020; 2155():23-39. PubMed ID: 32474865
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the non-neuronal cell contribution to Parkinson's disease pathogenesis using induced pluripotent stem cells.
Pons-Espinal M; Blasco-Agell L; Consiglio A
Cell Mol Life Sci; 2021 Mar; 78(5):2081-2094. PubMed ID: 33210214
[TBL] [Abstract][Full Text] [Related]
11. Docosahexaenoic acid promotes dopaminergic differentiation in induced pluripotent stem cells and inhibits teratoma formation in rats with Parkinson-like pathology.
Chang YL; Chen SJ; Kao CL; Hung SC; Ding DC; Yu CC; Chen YJ; Ku HH; Lin CP; Lee KH; Chen YC; Wang JJ; Hsu CC; Chen LK; Li HY; Chiou SH
Cell Transplant; 2012; 21(1):313-32. PubMed ID: 21669041
[TBL] [Abstract][Full Text] [Related]
12. Progress on stem cell research towards the treatment of Parkinson's disease.
Gibson SA; Gao GD; McDonagh K; Shen S
Stem Cell Res Ther; 2012 Apr; 3(2):11. PubMed ID: 22494990
[TBL] [Abstract][Full Text] [Related]
13. Efficiently Specified Ventral Midbrain Dopamine Neurons from Human Pluripotent Stem Cells Under Xeno-Free Conditions Restore Motor Deficits in Parkinsonian Rodents.
Niclis JC; Gantner CW; Alsanie WF; McDougall SJ; Bye CR; Elefanty AG; Stanley EG; Haynes JM; Pouton CW; Thompson LH; Parish CL
Stem Cells Transl Med; 2017 Mar; 6(3):937-948. PubMed ID: 28297587
[TBL] [Abstract][Full Text] [Related]
14. Midbrain Dopaminergic Neurons Differentiated from Human-Induced Pluripotent Stem Cells.
Tofoli FA; Semeano ATS; Oliveira-Giacomelli Á; Gonçalves MCB; Ferrari MFR; Veiga Pereira L; Ulrich H
Methods Mol Biol; 2019; 1919():97-118. PubMed ID: 30656624
[TBL] [Abstract][Full Text] [Related]
15. Strategies for bringing stem cell-derived dopamine neurons to the clinic-The NYSTEM trial.
Studer L
Prog Brain Res; 2017; 230():191-212. PubMed ID: 28552229
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson's disease.
Doi D; Magotani H; Kikuchi T; Ikeda M; Hiramatsu S; Yoshida K; Amano N; Nomura M; Umekage M; Morizane A; Takahashi J
Nat Commun; 2020 Jul; 11(1):3369. PubMed ID: 32632153
[TBL] [Abstract][Full Text] [Related]
17. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations.
Momcilovic O; Sivapatham R; Oron TR; Meyer M; Mooney S; Rao MS; Zeng X
PLoS One; 2016; 11(5):e0154890. PubMed ID: 27191603
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of Neural Stem Cells Derived from Induced Pluripotent Stem Cells into Dopaminergic Neurons.
Daadi MM
Methods Mol Biol; 2019; 1919():89-96. PubMed ID: 30656623
[TBL] [Abstract][Full Text] [Related]
19. Using Patient-Derived Induced Pluripotent Stem Cells to Identify Parkinson's Disease-Relevant Phenotypes.
Sison SL; Vermilyea SC; Emborg ME; Ebert AD
Curr Neurol Neurosci Rep; 2018 Oct; 18(12):84. PubMed ID: 30284665
[TBL] [Abstract][Full Text] [Related]
20. Differentiation and Characterization of Dopaminergic Neurons From Baboon Induced Pluripotent Stem Cells.
Grow DA; Simmons DV; Gomez JA; Wanat MJ; McCarrey JR; Paladini CA; Navara CS
Stem Cells Transl Med; 2016 Sep; 5(9):1133-44. PubMed ID: 27343168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
